Home/Chemotherapy Research and Practice/Article Record
Peer-Reviewed Article June 26, 2011

Neurotoxicity Caused by the Treatment with Platinum Analogues

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Chemotherapy Research and Practice
Publisher: Hindawi Publishing Corporation • Egypt • 2090-2107
DOI: https://doi.org/10.1155/2011/843019

Abstract

Platinum agents (cisplatin, carboplatin, and oxaliplatin) are a class of chemotherapy agents that have a broad spectrum of activity against several solid tumors. Toxicity to the peripheral nervous system is the major dose-limiting toxicity of at least some of the platinum drugs of clinical interest. Among the platinum compounds in clinical use, cisplatin is the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities. Carboplatin is generally considered to be less neurotoxic than cisplatin, but it is associated with a higher risk of neurological dysfunction if administered at high dose or in combination with agents considered to be neurotoxic. Oxaliplatin induces two types of peripheral neuropathy, acute and chronic. The incidence of oxaliplatin-induced neuropathy is related to various risk factors such as treatment schedule, cumulative dose, and time of infusion. To date, several neuroprotective agents including thiol compounds, vitamin E, various anticonvulsants, calcium-magnesium infusions, and other nonpharmacological strategies have been tested for their ability to prevent platinum-induced neurotoxicity with controversial results. Further studies on the prevention and treatment of neurotoxicity of platinum analogues are warranted.

Download Full Text PDFView at PublisherCrossref RecordCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

172
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.